AWM
KRYS icon

Abound Wealth Management’s Krystal Biotech KRYS Stock Holding History

Abound Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372 Hold
1
– – ﹤0.01% 1002
2026
Q1 		$259 Hold
1
– – ﹤0.01% 1159
2025
Q4 		$247 Hold
1
– – ﹤0.01% 1111
2025
Q3 		$177 Hold
1
– – ﹤0.01% 1159
2025
Q2 		$138 Hold
1
– – ﹤0.01% 1166
2025
Q1 		$181 Sell
1
-1
-50% -$168 ﹤0.01% 1024
2024
Q4 		$314 Hold
2
– – ﹤0.01% 880
2024
Q3 		$365 Buy
2
+1
+100% +$193 ﹤0.01% 935
2024
Q2 		$184 Buy
+1
New +$168 ﹤0.01% 1120

Other funds holding KRYS

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
CPIA
Cornell Pochily Investment Advisors Ithaca, New York $372M AUM 29.32% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
NWAG
Net Worth Advisory Group Sandy, Utah $397M AUM 29.92% 1-Year Est. Return

Abound Wealth Management's KRYS Position: Q2 2026 in Review

Abound Wealth Management held its Krystal Biotech (KRYS) position steady in Q2 2026 at 1 share worth $372. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

Abound Wealth Management first reported a position in KRYS in Q2 2024 and has held it in 9 quarters since. 31 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Abound Wealth Management held 1 share of Krystal Biotech worth $372 as of Q2 2026.
  • Abound Wealth Management left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1002 holding.
  • Abound Wealth Management first reported a position in Krystal Biotech in Q2 2024 and has held it in 9 quarters since.
  • 31 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.